InvestmentOct 23, 2026, 06:11 AM
Zai Lab Raises $250M in Private Placement
AI Summary
Zai Lab Limited announced the closing of a private placement financing, raising approximately $250 million before expenses. The company sold 11,340,000 American Depositary Shares (ADSs) at $22.04 per ADS to a group of accredited investors, including TCGX. The net proceeds are intended to fund the development of pipeline assets, notably zocilurtatug pelitecan (zoci), and for general corporate purposes. Additionally, Zai Lab published an updated corporate presentation detailing advancements in its drug development programs, including promising data for zoci in small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC), and for ZL-1503 in atopic dermatitis.
Key Highlights
- Zai Lab secured approximately $250 million in proceeds from a private placement.
- The private placement involved the sale of 11,340,000 American Depositary Shares (ADSs) at $22.04 per ADS.
- Proceeds will fund the development of pipeline assets, including zocilurtatug pelitecan (zoci).
- The financing was led by TCGX with participation from other investors including abrdn World Healthcare Fund, ADAR1 Capital Management, Balyasny Asset Management, Cormorant Asset Management, Frazier Life Sciences, RA Capital Management, RTW Investments, Sirenia Capital Management LP, Wellington Management, and Woodline Partners LP.
- Zai Lab presented updated corporate information, including data on zoci (ZL-1310) for SCLC and NEC, and ZL-1503 for atopic dermatitis.
Price Impact
More from ZLAB